AstraZeneca
AZN
559 hedge funds and large institutions have $19.3B invested in AstraZeneca in 2019 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 141 increasing their positions, 228 reducing their positions, and 68 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 68
9% more capital invested
Capital invested by funds: $17.7B → $19.3B (+$1.65B)
1% more funds holding
Funds holding: 556 → 559 (+3)
0.46% more ownership
Funds ownership: 18.37% → 18.83% (+0.46%)
10% less call options, than puts
Call options by funds: $91.5M | Put options by funds: $101M
38% less repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 228
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$246M |
| 2 |
Morgan Stanley
New York
|
+$205M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$97.5M |
| 4 |
O
OppenheimerFunds
New York
|
+$94.7M |
| 5 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$243M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$105M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$99.7M |
| 4 |
Jennison Associates
New York
|
-$92M |
| 5 |
EIP
Epoch Investment Partners
New York
|
-$46.8M |
AZN Hedge Fund Activity: Q1 2019 in Review
559 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2019, worth a combined $19.3B — up 9.4% from $17.7B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new AZN positions and 68 closed out — a net gain of 9 holders — while 141 added to existing stakes and 228 trimmed.
The largest buyer was Winslow Capital Management, opening a new position worth an estimated $246M. The largest seller was Bank of America, cutting an estimated $243M.
- 559 institutional investors held AstraZeneca (AZN) as of Q1 2019, up from 556 in Q4 2018.
- Funds reported $19.3B of AstraZeneca stock for Q1 2019, up 9.4% quarter-over-quarter.
- 77 funds opened new AstraZeneca positions in Q1 2019 and 68 closed out, a net change of +9 holders.
- The largest AstraZeneca buyer in Q1 2019 was Winslow Capital Management, an estimated $246M added.
- The largest AstraZeneca seller in Q1 2019 was Bank of America, an estimated $243M sold.
Based on aggregated 13F filings for Q1 2019.